method
two
phase
randomis
openlabel
trial
involv
healthi
adult
volunt
vrc
trial
done
three
centr
assess
plasmid
zika
viru
japanes
enceph
viru
chimera
vrc
done
one
centr
assess
plasmid
wildtyp
zika
viru
elig
particip
age
year
year
vrc
particip
randomli
assign
computergener
randomis
schedul
prepar
studi
statistician
particip
receiv
intramuscular
inject
mg
vaccin
vrc
particip
assign
receiv
vaccin
via
needl
syring
week
week
week
week
vrc
particip
assign
receiv
vaccin
week
via
singledos
needl
syring
inject
one
deltoid
splitdos
needl
syring
needlefre
inject
strati
devic
pharmajet
golden
co
usa
deltoid
trial
follow
volunt
month
primari
endpoint
safeti
assess
local
system
reactogen
day
vaccin
advers
event
day
vaccin
secondari
endpoint
trial
immunogen
week
last
vaccin
trial
regist
clinicaltrialsgov
number
find
vrc
enrol
particip
group
vrc
enrol
particip
group
one
particip
vrc
two
vrc
withdrew
one
dose
vaccin
includ
safeti
analys
vaccin
safe
well
toler
local
system
symptom
mild
moder
studi
pain
tender
inject
site
frequent
local
symptom
particip
vrc
vrc
malais
headach
frequent
system
symptom
respect
vrc
respect
vrc
particip
receiv
splitdos
vaccin
needlefre
inject
detect
posit
antibodi
respons
geometr
mean
titr
highest
across
group
trial
interpret
well
toler
advanc
phase
efficaci
test
zika
viru
latest
arbovir
infect
caus
epidem
diseas
western
hemispher
flaviviru
infect
human
be
known
year
judg
public
health
threat
outbreak
occur
yap
island
french
polynesia
america
southeast
asia
zika
viru
infect
caus
clinic
symptom
individu
macular
papular
rash
fever
arthriti
arthralgia
nonpurul
conjuncti
viti
myalgia
headach
retroorbit
pain
oedema
vomit
frequent
aed
spp
mosquito
main
sourc
infect
sexual
form
transmiss
possibl
lead
spread
nonendem
region
case
autochthon
zika
viru
infect
report
america
sinc
reveal
previous
unrecognis
sequela
decemb
pan
american
health
organ
issu
alert
link
zika
viru
infect
syndrom
congenit
malform
includ
microcephali
later
declar
zika
viru
public
health
emerg
intern
concern
causal
link
zika
viru
infect
syndrom
support
mechan
infectionrel
microcephali
un
known
epidemiolog
complex
effect
treatment
yet
avail
infect
often
sub
clinic
develop
prevent
vaccin
urgent
need
dna
vaccin
safe
immunogen
mani
pathogen
includ
flavivirus
although
none
licens
use
human
be
dna
vaccin
consist
plasmid
contain
code
dna
sequenc
virusspecif
antigen
promot
region
enabl
transcript
polyadenyl
sequenc
facilit
protein
translat
importantli
manufactur
process
safeti
immuno
genic
plasmid
establish
code
sequenc
chang
known
antigen
acceler
identif
novel
candid
vaccin
case
reduc
regulatori
requir
minim
preclin
toxic
data
establish
manufactur
technolog
previou
data
toxic
safeti
inher
dna
stabil
abil
elicit
antibodi
tcell
respons
make
dna
vaccin
attract
option
rapidli
respond
emerg
infecti
diseas
vaccin
research
center
vrc
nation
institut
allergi
infecti
diseas
niaid
nation
institut
health
nih
bethesda
md
usa
experi
develop
dna
vaccin
virus
includ
hiv
ebola
viru
sever
acut
respiratori
syndrom
coronaviru
influenza
viru
west
nile
viru
vrc
use
experi
develop
two
dna
vaccin
candid
zika
viru
use
west
nile
viru
vaccin
templat
expect
biolog
similar
member
flaviviru
genu
safe
induc
substanti
durabl
neutralis
activ
clinic
trial
plasmid
backbon
insert
sequenc
zika
viru
prm
e
gene
encod
protein
prm
prm
envelop
protein
e
e
respect
protein
express
mammalian
cell
assembl
subvir
particl
noninfecti
structur
antigen
similar
virion
particl
induc
protect
immun
respons
preclin
studi
done
parallel
manufactur
initi
product
choic
base
invitro
data
final
choic
base
anim
model
data
therefor
assess
two
dna
vaccin
candid
express
differ
prm
e
antigen
design
uncertain
preclin
evid
studi
zika
viru
recognis
pathogen
flaviviru
year
uncharacteris
pathogen
threat
public
health
limit
outbreak
pacif
region
brazil
led
recognit
emerg
infecti
diseas
previous
unknown
sequela
zika
viru
infect
notabl
congenit
abnorm
serv
impetu
acceler
vaccin
develop
vaccin
research
center
nation
institut
allergi
infecti
diseas
nation
institut
health
bethesda
md
usa
experi
develop
vaccin
protect
emerg
infecti
diseas
gener
especi
flavivirus
search
pubm
term
zika
viru
zika
vaccin
flaviviru
dna
vaccin
use
search
paramet
also
use
news
alert
pan
american
health
organ
center
diseas
control
prevent
identifi
report
retriev
paper
two
paper
provid
evid
immunogen
safeti
dna
vaccin
platform
given
via
needlefre
injector
system
administr
differ
flaviviru
west
nile
viru
dna
vaccin
platform
attract
context
allow
modif
previous
valid
plasmid
backbon
help
facilit
rapid
preclin
develop
manufactur
regulatori
approv
firstinhuman
vaccin
candid
also
found
use
needlefre
inject
devic
could
augment
immun
respons
dna
vaccin
compar
administr
via
needl
syring
use
previous
approv
plasmid
backbon
enabl
rapid
develop
approv
two
dna
vaccin
test
phase
studi
safeti
data
support
approach
human
immunogen
data
alon
relat
efficaci
current
exist
zika
viru
vaccin
therefor
human
data
need
assess
rel
data
deriv
anim
challeng
model
indic
candid
like
succeed
laterstag
trial
result
two
studi
find
nonhuman
primat
studi
provid
suffici
evid
support
test
region
endem
zika
viru
assess
efficaci
implic
avail
evid
safe
immunogen
previou
nonhuman
primat
studi
elicit
robust
neutralis
antibodi
respons
protect
anim
subsequ
viral
challeng
phase
clinic
trial
dna
vaccin
safe
well
toler
healthi
adult
led
product
detect
cellular
respons
neutralis
antibodi
respons
zika
viru
protein
administr
vaccin
needlefre
inject
result
highest
magnitud
humor
cellular
respons
clinic
data
indic
dna
vaccin
candid
viabl
option
use
zika
viru
infect
addit
clinic
trial
need
develop
determin
efficaci
atrisk
popul
previou
experi
develop
vaccin
emerg
diseas
show
rapid
develop
vaccin
requir
cooper
scientif
medic
regulatori
polit
commun
toward
common
goal
express
immunogen
data
would
predict
clinic
outcom
similar
e
region
contain
zika
viru
japanes
enceph
viru
sequenc
wherea
e
region
contain
wildtyp
zika
viru
sequenc
e
protein
produc
chimer
extracellular
region
zika
viru
origin
stem
transmembran
region
made
aminoacid
japanes
enceph
viru
japanes
enceph
viru
sequenc
use
improv
releas
subvir
particl
nonhuman
primat
thought
potenti
improv
immunogen
without
surfac
exposur
matur
particl
expect
contribut
otherwis
induct
protect
immun
japanes
enceph
viru
nonhuman
primat
two
zika
viru
vaccin
candid
induc
robust
neutralis
antibodi
re
pons
two
dose
given
week
apart
anim
receiv
two
mg
dose
two
mg
mg
dose
protect
viraemia
follow
zika
viru
challeng
week
vaccin
anim
broke
receiv
two
mg
dose
base
find
vaccin
advanc
phase
clinic
trial
assess
safeti
toler
immunogen
human
be
select
one
advanc
next
stage
develop
report
initi
find
trial
vrc
vrc
phase
randomis
openlabel
clinic
trial
zika
viru
dna
vaccin
candid
elig
particip
healthi
adult
age
year
vrc
year
vrc
without
abnorm
find
clinic
laboratori
test
medic
histori
physic
examin
volunt
vrc
recruit
nih
clinic
center
bethesda
md
univers
maryland
center
vaccin
develop
baltimor
md
usa
hope
clinic
emori
vaccin
center
decatur
ga
usa
vrc
recruit
nih
clinic
center
niaid
institut
review
board
review
approv
protocol
provid
oversight
studi
relianc
agreement
univers
maryland
emori
federalwid
assur
place
vrc
follow
depart
health
human
servic
guidelin
protect
human
be
research
particip
provid
written
inform
consent
enrol
trial
use
computergener
randomis
schedul
prepar
advanc
studi
statistician
assign
particip
vaccin
group
schedul
provid
studi
site
pharmaci
data
manag
centr
research
nurs
enrol
particip
vrc
particip
assign
four
differ
vaccin
schedul
vrc
particip
assign
three
group
singledos
splitdos
vaccin
vaccin
consist
phosphat
buffer
salin
purifi
plasmid
compris
mammalian
express
control
element
code
sequenc
zika
viru
prm
e
french
polynesia
isol
strain
standard
bacteri
origin
replic
select
element
vaccin
zika
viru
code
sequenc
modifi
substitut
japanes
enceph
viru
sequenc
stem
transmembran
region
e
protein
vaccin
prm
signal
sequenc
zika
viru
code
sequenc
exchang
analog
japanes
enceph
viru
region
improv
secret
zika
subvir
particl
transfect
cell
vaccin
manufactur
vrc
pilot
plant
oper
contract
leido
biomed
research
frederick
md
usa
accord
good
manufactur
practic
suppli
dose
mgml
mg
vaccin
given
vaccin
volunt
enrol
vrc
receiv
singl
intramuscular
inject
given
via
needl
syring
group
receiv
vaccin
week
group
week
group
week
group
week
vrc
origin
design
assess
deliv
needlefre
strati
devic
pharmajet
golden
co
usa
modif
need
deliv
dna
vaccin
high
viscos
made
time
trial
devic
therefor
use
vrc
trial
volunt
enrol
vrc
receiv
week
group
receiv
singl
dose
given
via
needl
syring
one
deltoid
group
receiv
split
dose
mg
one
deltoid
given
via
needl
syring
group
receiv
split
dose
mg
one
deltoid
given
via
syring
needlefre
devic
springpow
injector
pressuris
narrow
stream
vaccin
tissu
without
electropor
extern
appli
factor
primari
endpoint
vaccin
safeti
assess
local
system
reactogen
safeti
toler
monitor
clinic
laboratori
assess
particip
use
diari
card
record
local
system
reactogen
event
occur
day
inject
advers
event
occur
within
day
inject
record
clinic
staff
seriou
advers
event
record
entir
durat
studi
classifi
event
suspect
advers
reaction
view
investig
studi
sponsor
led
death
lifethreaten
event
admiss
hospit
pro
longat
hospit
stay
inabl
continu
normal
life
function
congenit
anomali
birth
defect
led
medic
surgic
intervent
prevent
one
outcom
use
fda
toxic
grade
scale
healthi
adult
adolesc
volunt
enrol
prevent
vaccin
clinic
trial
secondari
endpoint
immunogen
assess
report
viru
particl
neutralis
assay
antigenspecif
tcell
respons
vaccin
antibodi
respons
assess
measur
zikavirusspecif
neutralis
antibodi
previous
describ
report
viru
particl
assay
briefli
zika
viru
report
viru
particl
produc
human
embryon
kidney
cell
cotransfect
two
plasmid
one
encod
green
fluoresc
protein
express
west
nile
viru
replicon
encod
structur
protein
zika
viru
strain
zika
viru
report
viru
particl
incub
serial
threefold
dilut
heatinactiv
sera
duplic
technic
replic
ad
raji
cell
express
flaviviru
attach
factor
dcsignr
infect
cell
express
green
fluoresc
protein
count
h
infect
flow
cytometri
dilut
sera
need
neutralis
half
infect
event
ec
estim
nonlinear
regress
graphpad
prism
version
initi
dilut
sera
set
limit
detect
assay
ec
valu
neg
sampl
report
half
limit
detect
posit
antibodi
respons
defin
ec
greater
equal
use
intracellular
cytokin
stain
assess
tcell
respons
previous
describ
briefli
cryo
preserv
peripheralblood
mononuclear
cell
stimul
overlap
peptid
pool
length
aminoacid
overlap
aminoacid
zika
viru
e
protein
small
envelop
protein
peptid
pr
peripheralblood
mononuclear
cell
collect
baselin
time
vaccin
week
vaccin
data
analys
flowjo
softwar
version
treestar
ashland
usa
proport
total
cell
produc
interleukin
interferon
tumour
necrosi
factor
combin
cytokin
quantifi
boolean
gate
done
cytokineposit
gate
sum
calcul
total
proport
cytokineposit
cell
respond
peptid
pool
total
vaccin
respons
proport
cytokineposit
cell
respond
pool
peptid
sum
group
analys
backgroundsubtract
data
posit
chang
baselin
calcul
sampl
size
primarili
abil
identifi
seriou
advers
event
vrc
estim
particip
per
group
would
provid
power
detect
least
one
seriou
advers
event
within
group
true
rate
less
vrc
estim
particip
per
group
would
provid
power
detect
least
one
seriou
advers
event
within
group
true
rate
less
calcul
groupwis
magnitud
antibodi
respons
geometr
mean
titr
gmt
ci
use
twosampl
test
compar
group
gmt
within
across
trial
compar
magnitud
mean
tcell
respons
vaccin
wilcoxon
signedrank
test
within
group
wilcoxon
rank
sum
test
group
accord
trial
protocol
made
adjust
multipl
comparison
analys
immunogen
trial
power
detect
differ
statist
analys
r
version
trial
regist
clinicaltrialsgov
number
funder
studi
role
studi
design
data
collect
data
analysi
data
interpret
write
report
correspond
author
access
data
studi
final
respons
decis
submit
public
enrol
particip
screen
vrc
aug
sept
vrc
dec
april
figur
one
particip
vrc
two
vrc
withdrew
one
dose
vaccin
due
time
commit
preclud
trial
particip
includ
safeti
analys
followup
continu
expect
close
august
vrc
februari
vrc
vrc
group
vari
sex
race
age
bodymass
index
ethnic
similar
wherea
vrc
race
vari
notabl
tabl
vaccin
safe
well
toler
trial
local
system
reactogen
event
mild
moder
appendix
studi
pain
tender
inject
site
frequent
local
event
respect
vrc
tabl
one
seriou
advers
event
report
append
month
vaccin
deem
relat
vaccin
gmt
vaccin
vrc
greater
three
dose
vaccin
two
dose
tabl
appendix
posit
antibodi
respons
rang
week
final
vaccin
figur
highest
gmt
greatest
antibodi
respons
antibodi
titr
seen
group
particip
three
dose
vaccin
extend
time
second
third
dose
tabl
third
dose
gmt
boost
greater
gmt
second
dose
threedos
group
group
p
group
figur
gmt
achiev
vrc
substanti
higher
needlefre
inject
group
needl
syring
administr
group
tabl
posit
antibodi
respons
increas
singledos
needl
syring
administr
splitdos
needl
syring
administr
splitdos
needlefre
syring
administr
figur
gmt
vrc
group
greatest
across
group
studi
p
vs
group
vs
group
vrc
figur
neutralis
activ
week
last
vaccin
measur
report
viru
particl
assay
vrc
studi
sampl
collect
week
group
week
group
week
group
vrc
studi
sampl
collect
week
data
geometr
mean
titr
sd
deriv
two
four
independ
assay
per
sampl
dot
line
repres
limit
detect
assay
dilut
neg
sampl
report
half
limit
detect
dilut
ec
dilut
sera
requir
neutralis
half
infect
event
nsneedl
syring
vs
group
vs
group
vrc
appendix
splitdos
administr
vaccin
needl
syring
also
improv
gmt
compar
singledos
administr
via
method
appendix
two
group
receiv
needl
syring
antibodi
level
higher
split
dose
group
boost
third
dose
significantli
increas
gmt
greater
second
dose
group
ec
result
shown
appendix
week
last
vaccin
vrc
group
tcell
respons
pool
peptid
significantli
increas
cell
compar
baselin
tabl
figur
group
show
increas
respons
pool
peptid
greatest
tcell
respons
overal
seen
week
needlefre
administr
vrc
tabl
figur
cell
count
particip
receiv
via
needlefre
inject
increas
total
cytokin
respons
compar
baselin
pool
peptid
specif
eprotein
peptid
appendix
cell
count
group
also
increas
pool
peptid
specif
eprotein
peptid
appendix
given
split
dose
via
needl
syring
also
produc
signific
respons
pool
peptid
signific
respons
signific
respons
small
envelop
protein
pr
peptid
emerg
zika
viru
challeng
scientif
commun
address
rel
uncharacteris
pathogen
pose
substanti
threat
intern
public
health
although
symptom
zika
viru
infect
typic
mild
infect
pregnanc
asso
ciat
high
teratogen
risk
moreov
sexual
transmiss
travel
endem
region
might
extend
epidem
nonendem
region
without
requir
mosquito
vector
rapid
develop
vaccin
therefor
start
two
dna
vaccin
assess
safe
well
toler
advers
event
mild
vaccin
immunogen
greatest
effect
seen
given
split
dose
via
needlefre
inject
vrc
trial
despit
novelti
zika
viru
previou
knowledg
flaviviru
biolog
immun
point
toward
like
immunogen
correl
facilit
develop
zika
viru
vaccin
exampl
neutralis
activ
establish
correl
protect
licens
flaviviru
vaccin
studi
nonhuman
primat
neutralis
activ
correl
protect
viraemia
follow
vaccin
zika
viru
challeng
addit
role
antibodymedi
protect
zika
viru
infect
support
protect
infect
adopt
transfer
purifi
igg
mice
vaccin
dna
vaccin
zika
viru
tcelldeplet
mice
addit
humor
immun
cellular
immun
might
relev
particularli
tcell
respons
detect
human
be
flaviviru
infect
mind
dna
vaccin
platform
advantag
proteinbas
vaccin
induc
antibodi
substanti
tcell
respons
tcell
respons
necessari
optimum
memori
bcell
respons
cell
thought
facilit
viral
clearanc
import
fetal
protect
base
find
promis
advanc
later
stage
develop
particip
receiv
vaccin
needlefre
inject
split
dose
detect
antibodi
respons
neutralis
antibodi
tcell
respons
greatest
magnitud
addit
tcell
respons
greater
sinc
encod
japanes
enceph
viru
e
transmembran
sequenc
cellular
immun
respons
induc
vaccin
might
specif
viru
captur
intracellular
cytokin
stain
assay
might
abl
respond
zika
viru
wildtyp
zika
viru
e
transmembran
protein
plasmid
might
therefor
elicit
cellular
immun
respons
region
give
vaccin
advantag
immun
respons
differ
vaccin
deliveri
method
needlefre
injector
known
augment
dna
vaccin
respons
possibl
increas
dispers
inject
tissu
damag
increas
immunogen
gmt
splitdos
needlefre
deliveri
six
time
higher
singledos
deliveri
via
needl
syring
number
inject
also
import
gmt
achiev
given
split
dose
via
needl
syring
two
three
time
greater
seen
given
singl
dose
vaccin
schedul
vrc
trial
use
needl
syring
deliveri
therefor
could
compar
specif
variabl
respons
differ
outcom
two
trial
nonhuman
primat
studi
howev
administ
needlefre
inject
prevent
viraemia
effect
antibodi
induc
vaccin
investig
qualit
differ
might
contribut
differ
protect
capac
addit
dosereduct
studi
nonhuman
primat
done
defin
serolog
correl
protect
viraemia
base
avail
inform
need
shorten
assess
schedul
advanc
intern
placebocontrol
phase
efficaci
trial
vaccin
week
via
needlefre
deliveri
strati
devic
studi
aim
assess
safeti
immunogen
efficaci
popul
region
south
central
america
caribbean
usa
endem
zika
viru
basi
compar
serolog
correl
protect
viraemia
nonhuman
primat
vaccin
immunogen
human
volunt
serum
neutralis
activ
measur
report
viru
particl
assay
yield
highli
reproduc
sensit
result
assay
measur
inhibit
viral
entri
across
larg
dynam
rang
moreov
use
extens
defin
mechan
flaviviru
neutralis
reliabl
endpoint
determin
immun
correl
studi
nonhuman
primat
human
be
assay
correl
tradit
measur
neutralis
plaqu
reduct
neutralis
test
use
assess
previous
licens
flaviviru
vaccin
plaqu
reduct
neutralis
test
microneutralis
assay
howev
assess
entri
spread
replic
viru
cell
cultur
might
unabl
detect
replicationcompet
viru
neutralis
concentr
phase
trial
anoth
zika
viru
dna
vaccin
neither
plaqu
reduct
neutralis
test
microneutralis
assay
predict
whether
passiv
transfer
human
sera
would
protect
mice
zika
viru
challeng
ultim
efficaci
data
field
trial
need
establish
reliabl
correl
protect
use
refin
suffici
dose
schedul
effect
immun
much
still
need
done
vaccin
zika
viru
deploy
human
trial
far
show
data
healthi
popul
suitabl
openlabel
phase
trial
randomsi
placebocontrol
efficaci
trial
volunt
region
zika
viru
flavivirus
endem
still
need
import
limit
develop
zika
viru
vaccin
lack
establish
correl
protect
fetal
malform
whether
establish
correl
protect
clinic
diseas
nonteratogen
flavivirus
predict
prevent
fetal
diseas
zika
viru
unknown
whether
complet
prevent
viraemia
reduc
peak
viraemia
prevent
persist
viraemia
pregnant
mother
provid
suffici
fetal
protect
also
unknown
similar
situat
congenit
rubella
syndrom
sustain
epidemiolog
surveil
larg
popul
vaccin
individu
need
confirm
effect
congenit
infect
limit
studi
small
number
particip
howev
typic
phase
studi
studi
two
zikv
dna
vaccin
advanc
effort
quickli
curb
effect
zika
epidem
show
robust
neutralis
antibodi
tcell
respons
advanc
intern
phase
efficaci
trial
sever
vaccin
approach
also
pursu
find
human
studi
anoth
dna
vaccin
report
inactiv
vaccin
assess
human
be
differ
vaccin
might
design
distinct
target
popul
provid
variou
immun
respons
pattern
vari
durabl
joint
effort
continu
knowledg
immun
respons
zika
viru
deepen
guidanc
develop
definit
solut
epidem
improv
